N1-methylnicotinamide impairs gestational glucose tolerance in mice
Journal of Molecular Endocrinology · 2023
DOI: 10.1530/jme-23-0126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Endocrinology, 2023. Verfasst von Xiaojing Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China. Hauptthemen laut MEDLINE: Glucose Intolerance, Diabetes, Gestational, Insulin Resistance. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
N 1-methylnicotinamide (MNAM), a product of methylation of nicotinamide through nicotinamide N -methyltransferase, displays antidiabetic effects in male rodents. This study aimed to evaluate the ameliorative potential of MNAM on glucose metabolism in a gestational diabetes mellitus (GDM) model. C57BL/6N mice were fed with a high-fat diet (HFD) for 6 weeks before pregnancy and throughout gestation to establish the GDM model. Pregnant mice were treated with 0.3% or 1% MNAM during gestation. MNAM supplementation in CHOW diet and HFD both impaired glucose tolerance at gestational day 14.5 without changes in insulin tolerance. However, MNAM supplementation reduced hepatic lipid accumulation as well as mass and inflammation in visceral adipose tissue. MNAM treatment decreased GLUT4 mRNA and protein expression in skeletal muscle, where NAD+ salvage synthesis and antioxidant defenses were dampened. The NAD+/sirtuin system was enhanced in liver, which subsequently boosted hepatic gluconeogenesis. GLUT1 protein was diminished in placenta by MNAM. In addition, weight of placenta, fetus weight, and litter size were not affected by MNAM treatment. The decreased GLUT4 in skeletal muscle, boosted hepatic gluconeogenesis and dampened GLUT1 in placenta jointly contribute to the impairment of glucose tolerance tests by MNAM. Our data provide evidence for the careful usage of MNAM in treatment of GDM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.
- Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China.
- Institute of Neuroscience, Translational Medicine Institute, Xi'an Jiaotong University Health Science Center, Xi'an, China.
- Institute of Basic Medicine, School of Medicine, Tsinghua University, Beijing, China.
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
ORCID-Profile: Xiao Luo
Zitieren
APA
Wei, X., Tan, Y., Huang, J., Dong, X., Feng, W., Liu, T., Yang, Z., Yang, G., & Luo, X. (2023). N1-methylnicotinamide impairs gestational glucose tolerance in mice. Journal of Molecular Endocrinology. https://doi.org/10.1530/jme-23-0126
Vancouver
Wei X, Tan Y, Huang J, Dong X, Feng W, Liu T, et al. N1-methylnicotinamide impairs gestational glucose tolerance in mice. Journal of Molecular Endocrinology. 2023. doi:10.1530/jme-23-0126
BibTeX
@article{Wei2023,
author = {Wei, Xiaojing and Tan, Yutian and Huang, Jiaqi and Dong, Ximing and Feng, Weijie and Liu, Tanglin and Yang, Zhao and Yang, Guiying and Luo, Xiao},
title = {N1-methylnicotinamide impairs gestational glucose tolerance in mice},
journal = {Journal of Molecular Endocrinology},
year = {2023},
doi = {10.1530/jme-23-0126}
}
EUVIMED